Table 5 Predictive parameters of long-term outcomes (death and hospitalizations for MACE) (Cox model)
From: Galectin-3 predicts response and outcomes after cardiac resynchronization therapy
Univariate HR [CI 95%] | p* | Multivariate HR [CI 95%] | p* | |
|---|---|---|---|---|
Age ≥ 65 year-old | 1.89 [0.29–7.37] | 0.45 | ||
CAD | 3.62 [1.07–16.41] | 0.04 | 2.64 [0.72–12.54] | 0.15 |
Female sex | 0.86 [0.19–2.89] | 0.82 | ||
Minnesota ≥ 46 | 0.71 [0.22–2.72] | 0.59 | ||
Gal-3 ≥ 22 (ng/mL) | 4.33 [1.34–14.01] | 0.02 | 3.31 [1.00–11.34] | 0.05 |
LVEF ≥ 25% | 0.54 [0.17–1.85] | 0.31 | ||
LVESV (mL/m2) | 5.54 [0.53–43.11] | 0.14 | ||
Presence of LGE | 2.31 [0.73–8.67] | 0.16 | ||
LGE ≥ 14% | 2.20 [0.70–7.45] | 0.17 | ||
QRS < 150 ms | 3.20 [0.69–11.31] | 0.12 | ||
Selvester ≥ 24% | 1.84 [0.49–5.89] | 0.34 | ||
Creatinine clearance (mL/min/1.73 m2) | 0.98 [0.95–1.02] | 0.12 | ||
Diabetes | 1.24 [0.39–4.68] | 0.71 |